For Clinical AI Vendors

Make your AI easier for sponsors and CROs to approve, govern, and defend.

Sponsors and CROs do not only need to understand what your AI can do. They need to understand how it can be used in a regulated clinical workflow: who can rely on the output, what must escalate, what evidence is needed, who approves the action, and how oversight continues after deployment.

Corevident helps translate your product capability into the decision authority, evidence, approval, and oversight language regulated buyers need before controlled use.

Prepare Your AI for Regulated Buyer Review Schedule a Readiness Conversation →
The adoption gap

Product capability is not the only adoption barrier.

Clinical AI vendors often have strong models, workflows, and product value. But regulated buyers still need to answer a different set of questions before adoption:

Who owns the decision?
What requires human review?
What must escalate?
What evidence is retained?
Who approves use?
How is oversight maintained?

When those answers are unclear, adoption slows. Not because the product lacks value, but because the buyer cannot yet see how it fits into controlled clinical use.

Vendor offer

Clinical AI Controlled-Use Dossier

Corevident works through its AI-native operating environment to help vendors prepare a focused, vendor-facing operational dossier for regulated buyer review.

The dossier helps sponsors and CROs understand how your AI capability can be governed inside a clinical workflow, without forcing your team to become the buyer's governance, quality, or validation function.

The dossier clarifies:

Decision Authority™
Who can rely on, review, approve, or escalate AI-assisted work.
Evidence Requirements
What should be retained in the buyer's system of record.
Review & Escalation Rules
What needs human review, what escalates, and when.
Approval Requirements
What must be confirmed before AI-assisted work moves forward.
Oversight Model
What to monitor, adjust, restrict, or pause after deployment.
Buyer-Ready Use Case Narrative
How the AI capability fits into a regulated clinical workflow.
How Corevident works with vendors

From product value to governed buyer adoption.

Bring one AI capability, workflow, or buyer adoption challenge. Corevident works with your team to map how the capability enters regulated work, where human judgment remains required, what evidence should support use, and what oversight expectations the buyer will need to see.

The result is a clearer path from product value to governed buyer adoption.

When this is useful

Use this before regulated buyer conversations become stuck.

A sponsor or CRO asks how your AI is governed
Quality, Regulatory, or Clinical Operations raises adoption concerns
A pilot is moving toward broader deployment
Your product is entering a regulated clinical workflow
Buyer teams need clearer approval language
Your sales process needs stronger governance evidence
What this is not

Buyer enablement, not compliance certification.

Corevident does not certify, validate, or approve your product for regulatory compliance.

Corevident does not replace your buyer's Quality, Regulatory, validation, legal, clinical, or technology review processes.

The work helps make your AI capability easier for regulated buyers to understand, govern, and evaluate for controlled use.

Make the governance case as clearly as the product case.

Bring one AI capability, workflow, or buyer adoption challenge. Corevident will help translate it into the decision authority, evidence, approval, and oversight language sponsors and CROs need before controlled use.